Arrowstreet Capital Limited Partnership Reduces Stock Position in DexCom, Inc. (NASDAQ:DXCM)

Arrowstreet Capital Limited Partnership cut its holdings in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 32.7% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 54,825 shares of the medical device company's stock after selling 26,600 shares during the period. Arrowstreet Capital Limited Partnership's holdings in DexCom were worth $4,264,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Versant Capital Management Inc purchased a new stake in DexCom during the fourth quarter valued at about $25,000. Private Trust Co. NA boosted its stake in DexCom by 266.3% in the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock valued at $26,000 after acquiring an additional 245 shares during the period. TD Private Client Wealth LLC grew its position in shares of DexCom by 62.8% during the fourth quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock worth $34,000 after acquiring an additional 167 shares during the last quarter. Larson Financial Group LLC increased its position in DexCom by 40.5% in the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock valued at $37,000 after acquiring an additional 137 shares during the period. Finally, Heck Capital Advisors LLC bought a new stake in shares of DexCom during the 4th quarter worth about $38,000. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

DexCom Stock Performance

Shares of DXCM stock traded up $1.25 during trading hours on Monday, hitting $67.39. 166,835 shares of the company were exchanged, compared to its average volume of 4,120,563. The stock has a market capitalization of $26.42 billion, a price-to-earnings ratio of 47.12, a P/E/G ratio of 2.30 and a beta of 1.50. The firm has a fifty day simple moving average of $76.92 and a 200 day simple moving average of $76.68. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59. DexCom, Inc. has a 52-week low of $57.52 and a 52-week high of $139.24.

Remove Ads

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. Research analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently commented on DXCM. Citigroup upped their price target on shares of DexCom from $101.00 to $104.00 and gave the company a "buy" rating in a research report on Tuesday, March 4th. Baird R W raised DexCom from a "hold" rating to a "strong-buy" rating in a research report on Thursday, January 16th. Mizuho initiated coverage on shares of DexCom in a report on Thursday. They issued an "outperform" rating and a $85.00 price target on the stock. Redburn Atlantic raised shares of DexCom from a "neutral" rating to a "buy" rating and raised their price objective for the stock from $85.00 to $115.00 in a report on Monday, February 3rd. Finally, Robert W. Baird upgraded DexCom from a "neutral" rating to an "outperform" rating and boosted their target price for the stock from $86.00 to $104.00 in a research report on Thursday, January 16th. Five investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and three have given a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $99.00.

Insider Buying and Selling at DexCom

In other news, COO Jacob Steven Leach sold 2,634 shares of the business's stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $228,920.94. Following the sale, the chief operating officer now directly owns 268,644 shares of the company's stock, valued at $23,347,850.04. The trade was a 0.97 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Kevin R. Sayer sold 33,359 shares of the firm's stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the sale, the chief executive officer now owns 319,037 shares of the company's stock, valued at approximately $27,727,505.67. This represents a 9.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 105,009 shares of company stock valued at $8,044,178 in the last quarter. Company insiders own 0.30% of the company's stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.